<DOC>
	<DOC>NCT03055962</DOC>
	<brief_summary>Study E2609-J081-014 is a single-center, randomized, double-blind, placebo-controlled study conducted to evaluate the safety and tolerability of multiple oral doses of E2609 50 milligrams (mg), administered once daily for 14 days, in healthy Japanese participants aged 50 to 85 years.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy males and females Aged 50 to 85 years, inclusive at time of consent Body mass index (BMI) of 17.6 to 32 kilograms per meters squared (kg/m^2) at Screening Personal or family history of seizure disorder, symptomatic seizures (not including a history of simple febrile seizures in childhood) or any past or present medical condition which, in the opinion of the investigator has the potential to reduce seizure threshold (eg, history of head trauma or concussion, previous alcohol abuse, substance abuse) A history of cerebrovascular accident or nonvasovagalrelated loss of consciousness Any clinically significant findings on neurological examination A family history of Long QT Syndrome or a presence of other risk factors for Torsades de Pointes (TDP), such as hypokalemia, hypomagnesemia, or hypocalcemia History of cardiac arrhythmias, ischemic heart disease, or cerebrovascular disease A history of gastrointestinal surgery that may affect the pharmacokinetic profile of E2609 (eg, hepatectomy, nephrotomy, digestive organ resection) A known history of clinically significant drug or food allergies or presently experiencing significant seasonal allergy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy Participants</keyword>
	<keyword>E2609</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Japan</keyword>
</DOC>